Queudeville M, et al. – Researchers aimed at determining the role of blinatumomab in immunotargeting refractory or relapsed (R/R) acute lymphoblastic leukemia (ALL). In view of its efficacy and limited toxicity, they emphasized blinatumomab as a powerful therapeutic option in R/R ALL patients both adult and pediatric.